Recent 8-K filings for STXS

• July 15, 2026, 5:37 PM ET other material materiality 0.65 negative item 8.01item 9.01

  Stereotaxis completes Robocath acquisition; files risk factors highlighting dilution and integration risks

  Acquisition closed July 7, 2026; issued 6,269,628 Closing Shares (including warrants) and up to $25M earnout.

• July 9, 2026, 8:13 AM ET M&A materiality 0.65 positive item 3.02item 7.01item 8.01item 9.01

  Stereotaxis completes acquisition of Robocath for ~$20M in cash and stock

  Deal valued at ~$20M in cash and common stock; earnout up to $25M based on regulatory/commercial milestones.

• May 12, 2026, 4:10 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Stereotaxis reports Q1 revenue $6.3M, net loss $5.9M; guides FY26 rev >$40M; MAGiC FDA approved, Robocath acquisition

  Revenue $6.3M vs $7.5M YoY; net loss $5.9M; cash $14.6M, no debt.

• April 15, 2026, 7:59 PM ET M&A materiality 0.65 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements

  Stereotaxis to acquire Robocath for $20M initial plus up to $25M in earnouts

  Total consideration up to $45M: $20M upfront (cash/stock) plus earnouts of $10M (FDA approval) and $15M (commercial milestones).

• March 9, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis reports Q4 2025 revenue $8.6M (+36% YoY); guides FY2026 revenue >$40M

  Q4 2025 revenue $8.6M (+36% YoY); system rev $3.3M, recurring $5.3M.

• November 12, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Stereotaxis Reports Q3 2025 Revenue of $7.5M, Net Loss $6.5M; Guides Q4 Revenue Above $9M

  Q3 2025 revenue totaled $7.5M, with system revenue of $1.9M and recurring revenue of $5.6M.

• August 29, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Stereotaxis enters ATM equity agreement to sell up to $50M of common stock

  Agreement with Roth Capital Partners for at-the-market offering of up to $50M in common stock.

• August 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Stereotaxis Q2 revenue surges 95% to $8.8M; net loss narrows to $3.8M

  Revenue $8.8M (+95% YoY, +18% seq); system revenue $3.0M (vs $0.2M), recurring $5.8M (+35% YoY).

• July 17, 2025, 7:59 PM ET other material materiality 0.75 positive item 2.02item 8.01

  Stereotaxis pre-announces Q2 revenue $8.5-8.8M, up 90% YoY

  Revenue expected between $8.5M and $8.8M for Q2 2025, up ~15% sequentially and 90% YoY.

• July 17, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 7.01item 9.01

  Stereotaxis announces $12.5M registered direct offering at $2.00/share

  Gross proceeds of $12.5M from sale of common stock at $2.00/share; initial closing of $8.5M (4.25M shares) expected July 18, 2025.

• May 12, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Stereotaxis Q1 revenue $7.5M (+9% YoY); recurring up 29%; operating loss widens to $5.9M

  Revenue $7.5M (+9% YoY); system revenue $2.0M, recurring revenue $5.5M (+29% driven by Map-iT catheters).

• March 3, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Q4 revenue up 39% to $6.3M; expects double-digit revenue growth in 2025

  Q4 2024 revenue $6.3M (+39% YoY); full year $26.9M (+0.4% YoY).

• November 12, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Stereotaxis Q3 revenue $9.2M, up 18% YoY; net loss $6.2M; cash $13.3M at Oct end

  Revenue $9.2M (+18% YoY); system revenue $4.4M, recurring $4.8M.

• August 12, 2024, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Stereotaxis Q2 revenue down 43% to $4.5M; net loss $5.8M; expects H2 revenue >$14M

  Q2 revenue $4.5M vs $7.9M prior year; system revenue $0.2M due to hospital construction delays.

• May 16, 2024, 7:59 PM ET M&A materiality 0.75 neutral item 1.01item 3.02item 5.07 ◈ Shareholder Votes ×4◈ Material Agreements ×2

  Stereotaxis acquires APT for stock; earnouts based on revenue & regulatory milestones

  Acquires APT, a diagnostic catheter maker, for stock consideration; earnouts tied to global revenue and US/EU regulatory milestones for robotically-navigated catheters.

• May 13, 2024, 7:59 PM ET other material materiality 0.70 neutral item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Stereotaxis Q1 revenue $6.9M (+5% YoY); acquires Access Point Technologies for stock

  Q1 revenue $6.9M (+5% YoY); system revenue $2.6M, recurring $4.3M.

• March 4, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q4 revenue $4.6M, down 37% YoY; full year adjusted net loss $10.2M; guides Q1 2024 revenue ~$7M

  Q4 2023 revenue $4.6M vs $7.3M prior year; full year revenue $26.8M vs $28.1M.

• November 9, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q3 revenue $7.8M (+1% YoY); net loss $5.4M; cash $23M, no debt

  System revenue $3.5M from 2 Genesis systems; recurring revenue $4.3M (down 19% YoY, lost catheter royalties).

• August 10, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q2 revenue $7.9M (+28% YoY), net loss $5.0M, cash $23.9M

  Revenue $7.9M, up 28% YoY; system revenue $3.3M (two Genesis systems), recurring revenue $4.6M.

• June 15, 2023, 7:59 PM ET regulatory materiality 0.65 neutral item 8.01item 9.01

  Stereotaxis to initiate first-in-human trial for MAGiC catheter after CE Mark clinical data request

  Notified body requests clinical data for MAGiC catheter CE Mark under EU MDR; prior submission included preclinical data.

• May 9, 2023, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q1 revenue $6.5M, net loss $5.3M; reiterates double-digit growth outlook

  Revenue $6.5M vs $7.0M prior year; excluding catheter royalties, essentially flat.

• March 3, 2023, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Stereotaxis 2022 revenue $28.1M (-20% YoY); net loss $4.2M in Q4; guides double-digit growth in 2023

  Q4 revenue $7.3M (down from $8.2M); full year revenue $28.1M (down from $35.0M).

• November 10, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q3 2022 revenue $7.7M (-15% YoY); net loss widens to $4.9M

  Q3 2022 revenue $7.7M vs $9.1M prior year; system rev $2.4M, recurring $5.3M.

• August 9, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Stereotaxis Q2 revenue $6.2M, down 32% YoY; net loss $5.2M; cash $35.1M

  Revenue $6.2M vs $9.1M YoY; system revenue $0.6M, recurring $5.6M.

• May 10, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Stereotaxis Q1 revenue down 19% to $7.0M; net loss widens to $4.1M

  Revenue $7.0M vs $8.6M prior year; system revenue $1.6M, recurring $5.4M.

• March 3, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Stereotaxis reports 32% revenue growth in FY2021; adjusted net loss widens to $1.4M

  Full-year 2021 revenue $35.0M (up 32% from $26.6M); Q4 revenue $8.2M (up 21%).

• November 12, 2021, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Stereotaxis Q3 revenue $9.1M (+5% YoY); operating loss widens to $4.6M; sees 2022 system revenue doubling

  Revenue $9.1M (system $3.5M, recurring $5.3M); gross margin 52% with system margin 5% and recurring 86%.

• August 10, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Stereotaxis Q2 revenue $9.1M (+70% YoY); sees system revenue doubling in 2022

  Revenue up ~70% YoY to $9.1M; system revenue $2.7M, recurring $6.1M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.65 · Most common event earnings

9 positive 8 negative 19 neutral

source · STXS on sec.gov